RxDoctor Payments Data

Ajith Kumar, MD

Nephrology · Lewiston, IDNPI 1609952381

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 26.4% of the total. Reporting peaked in 2023 at $151 and has fallen 62.5% since, to $57 in 2025.

$672in general payments, 2019–2025

Across 37 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$177
  • Bayer$143
  • Novo Nordisk$119
  • Akebia Therapeutics Inc$64
  • Mallinckrodt Hospital Products Inc.$59
  • Vifor Pharma, Inc.$32
  • plus $76 from 4 others

What the payments were for

  • Food & beverage$672100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$672 in reported general payments places this provider in the 75th percentile of 30 nephrology providers in Idaho.

See all nephrology providers in Idaho

Medicare billing

Part B allowed, 2024
$285,109
Medicare patients
628
Services billed
2,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin31$33,059
ProsolParenteral Amino Acid 20% No.189$13,244
LokelmaSodium Zirconium Cyclosilicate17$11,253
FarxigaDapagliflozin Propanediol15$7,127
Torsemide333$6,226
Potassium Citrate ErPotassium Citrate12$5,937
Potassium Chloride116$4,961
Sevelamer Carbonate41$4,229
Cinacalcet Hcl24$4,020
Clonidine24$2,400
ClinisolParenteral Amino Acid 15% No.514$2,277
Calcium Acetate34$2,139
Calcitriol94$1,765
Losartan Potassium140$1,742
Amlodipine Besylate211$1,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$177$18,38032 claims
ANI Pharmaceuticals, Inc.Valsartan$18$47113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 30 nephrology providers in Idaho.

Other nephrology in Lewiston

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →